| ［1］ |
Bianchini G，Balko JM，Mayer IA，et al. Triple-negative breast cancer： challenges and opportunities of a heterogeneous disease［J］.Nat Rev Clin Oncol，2016，13（11）： 674-690.
|
| ［2］ |
Chen Y，Lin Y，Shu Y，et al. Interaction between N6-methyladenosine （m6A） modification and noncoding RNAs in cancer［J］.Mol Cancer，2020，19（1）： 94.
|
| ［3］ |
Siegel RL，Giaquinto AN，Jemal A. Cancer statistics，2024［J］.CA Cancer J Clin，2024，74（1）： 12-49.
|
| ［4］ |
Bray F，Laversanne M，Sung H，et al. Global cancer statistics 2022： GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin，2024，74（3）： 229-263.
|
| ［5］ |
Coles CE，Earl H，Anderson BO，et al. The lancet breast cancer commission［J］.Lancet，2024，403（10439）： 1895-1950.
|
| ［6］ |
Huang H，Weng H，Chen J. m6A modification in coding and non-coding RNAs： roles and therapeutic implications in cancer［J］.Cancer Cell，2020，37（3）： 270-288.
|
| ［7］ |
Petri BJ，Klinge CM. m6A readers，writers，erasers，and the m6A epitranscriptome in breast cancer［J］.J Mol Endocrinol，2022，70（2）： e220110.
|
| ［8］ |
Liu C，Yang Z，Li R，et al. Potential roles of N6-methyladenosine （m6A） in immune cells［J］.J Transl Med，2021，19（1）： 251.
|
| ［9］ |
Deng X，Su R，Weng H，et al. RNA N6-methyladenosine modification in cancers： current status and perspectives［J］.Cell Res，2018，28（5）： 507-517.
|
| ［10］ |
Fan S，Wang L. N6-methyladenosine-regulated LINC00675 suppress the proliferation，migration and invasion of breast cancer cells via inhibiting miR-513b-5p［J］.Bioengineered，2021，12（2）： 10690-10702.
|
| ［11］ |
Guo Y，Feng L. N6-methyladenosine-mediated upregulation of LINC00520 accelerates breast cancer progression via regulating miR-577/POSTN axis and downstream ILK/AKT/mTOR signaling pathway［J］.Arch Biochem Biophys，2022，729： 109381.
|
| ［12］ |
Xu Y，Song M，Hong Z，et al. The N6-methyladenosine METTL3 regulates tumorigenesis and glycolysis by mediating m6A methylation of the tumor suppressor LATS1 in breast cancer［J］.J Exp Clin Cancer Res，2023，42（1）： 10.
|
| ［13］ |
Wan W，Ao X，Chen Q，et al. METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer［J］.Mol Cancer，2022，21（1）： 60.
|
| ［14］ |
Zhao C，Ling X，Xia Y，et al. The m6A methyltransferase METTL3 controls epithelial-mesenchymal transition，migration and invasion of breast cancer through the MALAT1/miR-26b/HMGA2 axis［J］.Cancer Cell Int，2021，21（1）： 441.
|
| ［15］ |
Ren S，Zhang Y，Yang X，et al. N6-methyladenine-induced LINC00667 promoted breast cancer progression through m6A/KIAA1429 positive feedback loop［J］.Bioengineered，2022，13（5）： 13462-13473.
|
| ［16］ |
Chen C，Wang Y，Li Y，et al. VIRMA facilitates triple-negative breast cancer progression via increasing m6A-dependent KIF15 expression［J］. Discov Med，2023，35（178）： 787-795.
|
| ［17］ |
Qian JY，Gao J，Sun X，et al. KIAA1429 acts as an oncogenic factor in breast cancer by regulating CDK1 in an N6-methyladenosine-independent manner［J］.Oncogene，2019，38（33）： 6123-6141.
|
| ［18］ |
Niu Y，Lin Z，Wan A，et al. RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3［J］.Mol Cancer，2019，18（1）： 46.
|
| ［19］ |
Yi D，Xu F，Wang R，et al. Deciphering the map of METTL14‐mediated lncRNA m6A modification at the transcriptome‐wide level in breast cancer［J］.J Clin Lab Anal，2022，36（12）： e24754.
|
| ［20］ |
Lv CG，Cheng Y，Zhang L，et al. EXOSC2 mediates the pro-tumor role of WTAP in breast cancer cells via activating the Wnt/β-catenin signal［J］.Mol Biotechnol，2024，66（9）： 2569-2582.
|
| ［21］ |
Ou B，Liu Y，Yang X，et al. C5aR1-positive neutrophils promote breast cancer glycolysis through WTAP-dependent m6A methylation of ENO1［J］.Cell Death Dis，2021，12（8）： 737.
|
| ［22］ |
Park SH，Ju JS，Woo H，et al. The m6A writer RBM15 drives the growth of triple-negative breast cancer cells through the stimulation of serine and glycine metabolism［J］.Exp Mol Med，2024，56（6）： 1373-1387.
|
| ［23］ |
Zheng F，Du F，Qian H，et al. Expression and clinical prognostic value of m6A RNA methylation modification in breast cancer［J］.Biomark Res，2021，9（1）： 28.
|
| ［24］ |
Ou B，Liu Y，Gao Z，et al. Senescent neutrophils-derived exosomal piRNA-17560 promotes chemoresistance and EMT of breast cancer via FTO-mediated m6A demethylation［J］.Cell Death Dis，2022，13（10）： 905.
|
| ［25］ |
Yan Y，Ma J，Chen Q，et al. GAS5 regulated by FTO-mediated m6A modification suppresses cell proliferation via the IGF2BP2/QKI axis in breast cancer［J］.Discov Oncol，2024，15（1）： 182.
|
| ［26］ |
Zhang C，Samanta D，Lu H，et al. Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m6A-demethylation of NANOG mRNA［J］.Proc Natl Acad Sci USA，2016，113（14）： E2047-E2056.
|
| ［27］ |
Anita R，Paramasivam A，Priyadharsini JV，et al. The m6A readers YTHDF1 and YTHDF3 aberrations associated with metastasis and predict poor prognosis in breast cancer patients［J］.Am J Cancer Res，2020，10（8）： 2546-2554.
|
| ［28］ |
Chen H，Yu Y，Yang M，et al. YTHDF1 promotes breast cancer progression by facilitating FOXM1 translation in an m6A-dependent manner［J］.Cell Biosci，2022，12（1）： 19.
|
| ［29］ |
Lin Y，Jin X，Nie Q，et al. YTHDF3 facilitates triple-negative breast cancer progression and metastasis by stabilizing ZEB1 mRNA in an m6A-dependent manner［J］.Ann Transl Med，2022，10（2） ：83.
|
| ［30］ |
Li X，Zhang KJ，Hu Y，et al. YTHDF2 regulates cell growth and cycle by facilitating KDM1A mRNA stability［J］.Am J Pathol，2023，193（4）： 442-455.
|
| ［31］ |
Shi J，Zhang Q，Yin X，et al. Stabilization of IGF2BP1 by USP10 promotes breast cancer metastasis via CPT1A in an m6A-dependent manner［J］.Int J Biol Sci，2023，19（2）： 449-464.
|
| ［32］ |
Zhong S，Lin Z，Chen H，et al. The m6A-related gene signature for predicting the prognosis of breast cancer［J］.Peer J，2021，9： e11561.
|
| ［33］ |
Zhang X，Shi L，Sun HD，et al. IGF2BP3 mediates the mRNA degradation of NF1 to promote triple‐negative breast cancer progression via an m6A‐dependent manner［J］.Clin Transl Med，2023，13（9）： e1427.
|
| ［34］ |
Wu Y，Zhao W，Liu Y，et al. Function of HNRNPC in breast cancer cells by controlling the dsRNA‐induced interferon response［J］.EMBO J，2018，37（23）： e99017.
|
| ［35］ |
Xu W，Huang Z，Xiao Y，et al. HNRNPC promotes estrogen receptor‐positive breast cancer cell cycle by stabilizing WDR77 mRNA in an m6A‐dependent manner［J］.Mol Carcinog，2024，63（5）： 859-873.
|
| ［36］ |
Lian B，Yan S，Li J，et al. HNRNPC promotes collagen fiber alignment and immune evasion in breast cancer via activation of the VIRMA-mediated TFAP2A/DDR1 axis［J］.Mol Med，2023，29（1）： 103.
|
| ［37］ |
Ayoufu A，Yi L，Tuersuntuoheti M，et al. HNRNPA2B1 is a potential biomarker of breast cancer related to prognosis and immune infiltration［J］.Aging （Albany NY），2023，15（17）： 8712-8728.
|
| ［38］ |
Jin T，Yang L，Chang C，et al. HnRNPA2B1 ISGylation regulates m6A‐tagged mRNA selective export via ALYREF/NXF1 complex to foster breast cancer development［J］.Adv Sci （Weinh），2024，11（24）： e2307639.
|
| ［39］ |
Li S，Jiang F，Chen F，et al. Effect of m6A methyltransferase METTL3‐mediated MALAT1/E2F1/AGR2 axis on adriamycin resistance in breast cancer［J］.J Biochem Mol Toxicol，2022，36（1）： e22922.
|
| ［40］ |
Zhou S，Sheng L，Zhang L，et al. METTL3/IGF2BP3-regulated m6A modification of HYOU1 confers doxorubicin resistance in breast cancer［J］.Biochim Biophys Acta Gen Subj，2024，1868（3）： 130542.
|
| ［41］ |
Wang J，Xu J，Zheng J. A1BG-AS1 promotes adriamycin resistance of breast cancer by recruiting IGF2BP2 to upregulate ABCB1 in an m6A-dependent manner［J］.Sci Rep，2023，13（1）： 20730.
|
| ［42］ |
Wei L，Bai Y，Na L，et al. E2F3 induces DNA damage repair，stem-like properties and therapy resistance in breast cancer［J］.Biochim Biophys Acta Mol Basis Dis，2023，1869（8）： 166816.
|
| ［43］ |
Liu X，Li P，Huang Y，et al. m6A demethylase ALKBH5 regulates FOXO1 mRNA stability and chemoresistance in triple-negative breast cancer［J］.Redox Biol，2024，69： 102993.
|
| ［44］ |
Jing L，Lan L，Mingxin Z，et al. METTL3/LINC00662/miR-186-5p feedback loop regulates docetaxel resistance in triple negative breast cancer［J］.Sci Rep，2022，12（1）： 16715.
|
| ［45］ |
Ou X，Tan Y，Xie J，et al. Methylation of GPRC5A promotes liver metastasis and docetaxel resistance through activating mTOR signaling pathway in triple negative breast cancer［J］.Drug Resist Updat，2024，73： 101063.
|
| ［46］ |
Gao L，Qiao L，Li Y，et al. ALKBH5 regulates paclitaxel resistance in NSCLC via inhibiting CEMIP-mediated EMT［J］.Toxicol Appl Pharmacol，2024，483： 116807.
|
| ［47］ |
Zhao C，Zhang F，Tian Y，et al. m6A reader IGF2BP1 reduces the sensitivity of nasopharyngeal carcinoma cells to Taxol by upregulation of AKT2［J］.Anticancer Drugs，2024，35（6）： 501-511.
|
| ［48］ |
Zhu M，Liu Y，Song Y，et al. The role of METTL3-mediated N6-methyladenosine （m6A） of JPH2 mRNA in cyclophosphamide-induced cardiotoxicity［J］.Front Cardiovasc Med，2021，8： 763469.
|
| ［49］ |
Zhang K，Zhang T，Yang Y，et al. N6-methyladenosine-mediated LDHA induction potentiates chemoresistance of colorectal cancer cells through metabolic reprogramming［J］.Theranostics，2022，12（10）： 4802-4817.
|
| ［50］ |
Sun Y，Dong D，Xia Y，et al. YTHDF1 promotes breast cancer cell growth，DNA damage repair and chemoresistance［J］.Cell Death Dis，2022，13（3）： 230.
|
| ［51］ |
Yu H，Yang X，Tang J，et al. ALKBH5 inhibited cell proliferation and sensitized bladder cancer cells to cisplatin by m6A-CK2α-mediated glycolysis［J］.Mol Ther Nucleic Acids，2021，23： 27-41.
|
| ［52］ |
Wei W，Sun J，Zhang H，et al. Circ0008399 interaction with WTAP promotes assembly and activity of the m6A methyltransferase complex and promotes cisplatin resistance in bladder cancer［J］.Cancer Res，2021，81（24）： 6142-6156.
|
| ［53］ |
Wei J，Yin Y，Zhou J，et al. METTL3 potentiates resistance to cisplatin through m6A modification of TFAP2C in seminoma［J］.J Cell Mol Med，2020，24（19）： 11366-11380.
|